EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

Julia Weisinger iD, Jehane Fadlallah, Bérangère Joly, Agnès Veyradier, Paul Coppo iD

British Journal of Haematology · 2025-06 · 206 (6) · 1560-1570

DOI: 10.1111/bjh.20101 ↗

At a glance

Übersichtsarbeit in British Journal of Haematology, published online on 2025-04-24. Written by Julia Weisinger and 4 co-authors. Institution: Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and So…. Major MEDLINE topics: Rituximab, Purpura, Thrombotic Thrombocytopenic. Cited 12 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Plan for Rare Diseases of the French Ministry of Health, Filière de Santé Maladies Rares Immuno-Hématologiques, French Ministry of Health.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The use of rituximab, a B‐cell‐depleting agent as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP), is the current standard of care. However, for patients refractory to rituximab or for those with contraindications, further treatment guidelines are scarce. Standard immunosuppressive or chemotherapeutic agents were used routinely in the past, but most of the data proving their efficacy are stemming from experience before the routine use of rituximab. Ciclosporin A and azathioprine seem to be effective in the pre‐emptive setting, but their safety profile might limit their use. Extended or intensive rituximab administration may overcome refractoriness in some patients. New therapeutic options, such as new generation anti‐CD20 antibodies like obinutuzumab or the plasma cell‐directed therapy daratumumab, showed important efficacy in iTTP after rituximab failure, with a favourable safety profile. There are no available comparative studies for pre‐emptive treatment options in iTTP; therefore, data from large databases and multicentre studies are essential. In this review, we summarize the possible treatment options in case of rituximab failure in iTTP and try to provide a recommendation based on available literature and our own experience.

Subjects

MeSH terms (MEDLINE)

RituximabPurpura, Thrombotic ThrombocytopenicHumansTreatment FailureImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Author keywords

TTPpre‐emptive therapyrituximab

Substances

RituximabImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Authors and institutions

  • Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne Université, Paris, France.
  • Service d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Paris, France.
  • Service d'Hématologie biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris Nord, Université Paris Cité, Paris, France.

ORCID profiles: Julia Weisinger, Paul Coppo

Funding

  • National Plan for Rare Diseases of the French Ministry of Health
  • Filière de Santé Maladies Rares Immuno-Hématologiques
  • French Ministry of Health
  • European Union MSCA TOLERATE

Cite

APA

Weisinger, J., Fadlallah, J., Joly, B., Veyradier, A., & Coppo, P. (2025). How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology, 206(6), 1560-1570. https://doi.org/10.1111/bjh.20101

Vancouver

Weisinger J, Fadlallah J, Joly B, Veyradier A, Coppo P. How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology. 2025;206(6):1560-1570. doi:10.1111/bjh.20101

BibTeX
@article{Weisinger2025,
  author = {Weisinger, Julia and Fadlallah, Jehane and Joly, Bérangère and Veyradier, Agnès and Coppo, Paul},
  title = {How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {6},
  pages = {1560--1570},
  doi = {10.1111/bjh.20101}
}
Start for free →